[Dibekacin treatment of infectious complications of abdominal surgery].

Major abdominal surgery often involves severe postoperative infections with various pathogens: enterobacteriaceae, staphylococcus and anaerobic bacteria. For this reason a strong antibiotherapy can be necessary in the case of an infectious disease. Dibekacin was administered at a daily dose of 3 mg/kg to 22 patients suffering from very severe postoperative infection.

[Dibekacin in the treatment of septicemia].

During an open multicentric trial (17 centers), we have treated 62 septicemia by dibekacin, alone or associated with other antibacterial drugs. Taking into account the degree of severity of these patients, the results are considered satisfactory in 47 patients. 15 failures were noted (including 9 deaths).

[Treatment of urinary tract infections by dibekacin].

In this cooperative trial, 181 patients with various urinary tract infections were treated by dibekacin, a new hemi-synthetic aminoglycoside. Clinical and bacteriological results confirm the efficacy of dibekacin in this indication. Local and systemic tolerance, and thus renal and cochleo-vestibular, were very satisfactory.